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Abstract
Familial hypercholesterolemia (FH) is a common genetic disorder caused by mutations of the LDL-receptor gene and transmitted as a co-
dominant trait. However, there are some forms of hypercholesterolemia which have a recessive type of transmission. We have identified a
subject with the clinical phenotype of heterozygous FH whose parents had normal plasma lipid values, suggesting a recessive type of
transmission. The analysis of the LDL-receptor gene revealed that the patient was heterozygous for a G>C transversion in exon 4, which
results in a serine for cysteine substitution at position 88 (C88S) of the receptor protein. Since this novel mutation was not found in the
proband’s parents and non-paternity was excluded, we concluded that the patient was a carrier of a ‘‘de novo’’ mutation. Haplotype analysis
of LDL-receptor locus indicated that this ‘‘de novo’’ mutation occurred in the paternal germ line. The C88S mutation is the likely cause of
LDL-receptor defect as it was present in the proband’s hypercholesterolemic son and was not found in 200 chromosomes of control subjects.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Monogenic hypercholesterolemias represent a heteroge-
neous group of disorders which includes: (i) familial hyper-
cholesterolemia (FH) due to a large variety of mutations of
LDL-receptor gene [1–3]; (ii) familial defective Apo B-100
(FDB) caused by some mutations of apoB gene resulting in
defective binding of LDL-apoB100 to the LDL-receptor
[4,5]; (iii) autosomal recessive hypercholesterolemia
(ARH), a recently characterised disorder due to mutation
of a putative LDL-receptor adaptor protein [6]. Linkage
studies in some large families with monogenic hypercho-
lesterolemia have suggested the presence of other genes
which have not been identified yet [7].
On clinical grounds, the criteria for diagnosis of FH and
FDB are based on the presence of: (i) LDL cholesterol levels
above the 95th percentile of the distribution in the general
population; (ii) tendon xanthomatosis in the proband or in a
first-degree relative, or alternatively, severe hypercholester-
olemia in some prepuberal children of the proband’s family;
(iii) a vertical transmission of hypercholesterolemia and a
bimodal distribution of plasma LDL cholesterol levels in the
proband’s family.
The diagnosis of FDB is usually based on the finding of
four mutations of Apo B gene, all causing single amino acid
substitutions (R3500Q, R3500W, R3531C and R3480W)
[4,5], known to reduce Apo B binding to LDL-receptor. The
molecular diagnosis of FH is based on the demonstration of:
(i) a mutation in the LDL-receptor gene which has previ-
ously been shown to cause a functional defect in cultured
cells or has been documented in other FH patients (see
http://www.ucl.ac.uk/fh); (ii) a novel mutation which un-
equivocally co-segregates with FH in the proband’s family
and has not been found in at least 100 randomly selected
control subjects. Since FH is characterised by a striking
allelic heterogeneity (>700 mutations of LDL-receptor gene
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have been reported so far), in most cases, the molecular
diagnosis of FH requires the sequence of the entire LDL-
receptor gene.
Although less frequent, primary hypercholesterolemia
may be transmitted as a recessive trait. In the few reported
families in which recessive transmission is suspected for the
presence of consanguinity, probands have LDL cholesterol
levels which are higher than those usually observed in
heterozygous FH and resemble those found in FH homo-
zygotes [6,8,9].
An apparently recessive mode of transmission of FH may
be observed in the case of the occurrence of a ‘‘de novo’’
mutation of the LDL-receptor gene [10–12]. In the present
study, we describe a family in which, because of the
presence of a ‘‘de novo’’ mutation, an apparently recessive
mode of transmission coexists with the classical co-domi-
nant transmission of FH.
2. Materials and methods
2.1. Proband
The proband was a 47-year-old white male who at the
age of 43 had suffered from a myocardial infarction. He had
smoked 40 cigarettes per day since the age of 20 but quit at
the age of 43. Coronary angiography, performed at age 44,
showed a critical stenosis (95%) in the left anterior descend-
ing artery that was successfully treated by PTCA. During
routine blood examination at age 35, he was found to have
elevated plasma LDL cholesterol level (9.10 mmol/l), but he
did not take any lipid-lowering drug until the age of 43. At
the age of 38, he underwent cholecystectomy for gallstone
disease. At the present, tendon xanthomas, xanthelasmas
and arcus corneae are not detectable. The proband’s parents
were apparently unrelated.
2.2. Analysis of LDL-receptor gene
Genomic DNA of the proband and his family members
was extracted from peripheral blood leukocytes by a stan-
dard procedure [13]. PCR amplifications of promoter re-
gion, all exons and exon–intron boundaries of LDL-re-
ceptor gene were performed as reported previously [14],
using the primers reported by Jensen et al. [15]. PCR am-
plified fragments were sequenced directly by using CEQk
2000XL Analysis System (Beckman Coulter, Inc., Fullerton,
CA).
For the screening of the LDL-R mutation found in the
proband, we amplified the 5Vhalf of exon 4 (355 bp) by
using the following primers: 5V-GTTGGGAGACTTCA-
CACGGTGATGG-3V(forward primer), 5V-ACTTAGG-
CAGTGGAACTCGAAGGCC-3V(reverse primer); the
amplification conditions were: 94 jC for 5 min, followed
by 30 cycles of denaturation at 94 jC for 30 s, annealing at
65 jC for 30 s, extension at 72 jC for 1 min, final extension
at 72 jC for 7 min. The amplification product was digested
with 6 U of Aat II (Roche Diagnostic) at 37 jC for 4 h. The
presence of the mutation, which introduces an Aat II
restriction site, generates two fragments (293 and 62 bp,
respectively).
2.3. Haplotype analysis at LDL-R locus
The haplotype co-segregating with the mutation was
identified by the analysis of the polymorphic tetranucleotide
microsatellite D19S394, which is 250 kb telomeric to the
LDL-R gene and of the intragenic Ava II polymorphism
located in exon 13.
The PCR amplification of D19S394 microsatellite was
carried out with a modification of the method described by
Day et al. [16]. Briefly, the amplification mix included 200
ng of genomic DNA, 1.25 U of Platinum Taq polymerase
(Gibco BRL-Life Technologies, Italia, Srl), 200 AM each
of the dNTPs, 1 solvent enhancer provided with the
polymerase, 5 pmol of each primer (forward, 5V-AGACTA-
CAGTGAGCTGTGG-3Vand reverse 5V-GTGTTCCTAAC-
TACCAGGC-3V, without any fluorescent label) and 1.5
mM of MgSO4. The PCR reaction consisted in 35 cycles
(95 jC for 30 s/56 jC for 30 s/68 jC for 1 min) that were
preceded by a 2 min denaturation at 95 jC and followed
by a 7 min extension at 68 jC. The PCR product was
directly analyzed with the Agilent 2100 Bioanalyzer (Agi-
lent Technologies, Waldbronn, Germany) for high-voltage
capillary electrophoresis on microchips and laser-induced
fluorescence (LIF) detection, as previously described [17].
Allele sizes provided by this instrument equipped with
Agilent DNA500 LabChip (for sizing dsDNA fragments
up to 500 bp) and its specific DNA sizing ladder were
rounded to the nearest conventional allele value and
expressed as the number of variable repeats found in each
allele.
The Ava II (C>T) polymorphism was analyzed with the
method described by Humphries et al. [18].
2.4. Paternity testing
A small aliquot of genomic DNA was amplified by PCR
[19,20]. Three multiplex reactions were performed for the
following markers: Hum F13B, TPOX, FGA, CSF1PO,
F13A01, D8S1179, LPL, TH01, VWA31/A, FES/FPS,
D18S51, D19S253, D21S11.
An aliquot of the amplification reaction (0.5–2 Al) was
mixed with 6 fmol of commercial internal standard GS 2500
(ABD, USA), denatured at 90 jC for 2 min and loaded onto
a 6% polyacrylamide denaturing gel. Samples were electro-
phoresed at constant power (36 W) for 5 h in an Applied
Biosystem Automated DNA sequencer 373A Leon and
sized by Genescan 672 software (ABD, USA) employing
the Local Southern method.
Informed consent was obtained from all subjects inves-
tigated. The study protocol was approved by the institu-
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tional human investigation committee of each participating
institution.
3. Results
Table 1 shows the clinical features and plasma lipids in
the proband’s family. While serum total cholesterol, LDL
cholesterol and Apo B in the proband’s parents were within
the normal level, the values found in the proband were
consistent with the diagnosis of primary hypercholesterole-
mia.
High LDL cholesterol and Apo B levels were also ob-
served in the proband’s 9-year-old son, suggesting a father
to son transmission of the disorder.
The sequence of LDL-R gene revealed that the proband
was heterozygous for G>C transversion in exon 4, which
converts the codon TGC for cysteine at position 88 into a
codon TCC for serine (Fig. 1). This mutation, which in-
volves the repeat 3 of the binding domain, was found in the
proband’s son but not in the proband’s parents.
Table 1
Clinical and biochemical features of proband’s family
Proband Father Mother Spouse Son
Age (years) 47 76 72 44 9
BMI (kg/m2) 25.3 23.1 32.0 19.5 20.3
Cholesterol 10.78 3.51 4.99 5.37 9.51
LDL cholesterol 8.97 1.99 2.97 2.77 7.14
HDL cholesterol 1.34 1.21 1.19 1.76 1.63
Triglycerides 1.30 0.83 2.31 1.86 1.66
Apo AI 144 129 148 170 156
Apo B 168 52 78 75 152
Lipid values (mmol/l), apolipoproteins (mg/dl).
Fig. 1. Partial sequence (antisense) of exon 4 showing the C>G transversion at nucleotide 326 of the LDL receptor cDNA in the proband (panel A) and his son
(panel B). The mutation is not present in proband’s parents (panels C and D).
Table 2
Parental diagnosis




1 F13B 10/8 9/6 10/9 10
2 TPOX 8/8 11/8 8/11 (8)
4 FGA 21/22 23/22 21/23 21
5 CSF1PO 10/11 11/12 10/11 10
7 F13A01 6/3.2 15/4 6/15 6
8 D8S1179 16/15 14/13 16/14 16
8 LPL 11/9 13/10 11/13 11
11 TH01 9.3/9.3 9/6 9.3/9 9.3
12 VWA31/A 15/16 18/17 15/18 15
15 FES/FPS 11/10 12/10 11/12 11
18 D18S51 17/17 16/17 17/16 (17)
19 D19S253 12/11 7/11 12/7 12
21 D21S11 30/28 32.2/32.2 30/32.2 30
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Paternity testing was performed using a battery of 13
short tandem repeats located in 12 different chromosomes
(Table 2). The result of this analysis defined a hypothesis of
paternity with a casual sharing of 1.5 10 8. The like-
lihood of paternity was therefore 99.998%.
The analysis of genetic markers within or close to LDL-R
gene allowed the identification of the haplotype co-segre-
gating with the mutation. The segregation of this haplotype
in the pedigree indicated that the mutational event occurred
in the germ line of the proband’s father (Fig. 2). This
mutation was not found in DNA samples from 100 ran-
domly selected control subjects.
4. Discussion
In this study, we report a ‘‘de novo’’ mutation of LDL-
receptor gene in a subject with severe hypercholesterolemia
and a history of myocardial infarction. Since non-paternity
was excluded, the fact that the proband’s parents had normal
cholesterol raised three possible hypotheses: (i) the pro-
band’s parents were carriers of mutations in some genes
causing recessive hypercholesterolemia [6]; (ii) one of the
proband’s parents was a carrier of an LDL-gene mutation,
the effect of which was abolished by the concomitant
presence of an LDL-lowering gene (lack of penetrance);
(iii) the presence of a ‘‘de novo mutation’’ of LDL-receptor
gene. The finding that neither of the parents was a carrier of
the mutation of LDL-receptor gene found in the proband
and the observation that this mutation was present in the
proband’s son substantiated the hypothesis of a ‘‘de novo’’
germ line mutation, transmitted as a co-dominant trait to the
next generation.
To the best of our knowledge, this is the fifth report of a
‘‘de novo’’ mutation of the LDL-receptor gene associated
with the clinical phenotype of FH. The first ‘‘de novo’’
mutation was an 18 bp duplication in exon 4 found in an
FH-Afrikaner male subject who transmitted this mutation to
his daughter [10]. The second mutation (a deletion of exons
14 and 15) was detected in a Finnish FH-compound
heterozygote [11].
The third mutation was reported by our group in an 11-
year-old boy with no family history of familial hypercho-
lesterolemia. In the latter case, the mutation was T>A
transversion in exon 1, which causes an arginine for
tryptophane substitution at the  12 position of the signal
peptide (W-12R) of the LDL-receptor [12]. The fourth
mutation (a splicing defect, 313 + 1 g>a) was found in an
African FH subject [21].
The mutation discovered in our proband eliminates a
cysteine in the third repeat of the ligand binding domain,
where cysteine residues play a crucial role in the proper
folding of this domain. It is likely that this substitution is the
cause of FH in our proband for four reasons: (i) cysteine at
position 88 is highly conserved in LDL-receptor of various
species (e.g. rabbit and xenopous) [22,23]; (ii) substitutions
of this cysteine with other amino acids (C88R, C88Y and
C88F) have been reported in FH patients (see http://www.
ucl.ac.uk/fh); (iii) C88S was not found in 100 randomly
selected control subjects; (iv) C88S is present in the pro-
band’s hypercholesterolemic son. It is possible that C88S
reduces LDL binding and, in view of the misfolding of the
LDL-R binding domain, causes an increased intracellular
degradation of LDL-receptor protein [1].
The fact that only few ‘‘de novo’’ mutations of LDL-
receptor gene have been documented so far is surprising in
view of the large number of mutations of this gene found
to date and its presence in several hot spots for mutations
(CG dinucleotides, direct and inverted short repeats in
coding sequences and the relatively large number of Alu
sequences). It is possible that this low number of reported
‘‘de novo’’ mutations reflects a selection bias, since
sporadic cases of primary hypercholesterolemia, in the ab-
sence of a positive family history of FH (tendon xantho-
mas, hypercholesterolemia, premature cardiovascular
disease, etc.) or of sufficient family data, are not diagnosed
as FH, or they are labelled as polygenic hypercholester-
olemia. Since most of these cases are probably not
genotyped at the LDL-receptor locus, their precise etiology
remains to be defined. In view of these considerations, we
do not have an estimate of the frequency of ‘‘de novo’’
mutations of the LDL-receptor gene causing FH in the
population.
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Fig. 2. Proband’s pedigree. The alleles of the microsatellite D19S394
(number of repeats) and of the Ava II polymorphism are shown below each
subject. The haplotype co-segregating with the mutation, seven repeats and
Ava II ( ), indicates that the mutational event occurred in the paternal
germ line.
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